List of Aristada Initio Kit drug patents

Aristada Initio Kit is owned by Alkermes Inc.

Aristada Initio Kit contains Aripiprazole Lauroxil.

Aristada Initio Kit has a total of 8 drug patents out of which 0 drug patents have expired.

Aristada Initio Kit was authorised for market use on 29 June, 2018.

Aristada Initio Kit is available in suspension, extended release;intramuscular dosage forms.

Aristada Initio Kit can be used as treatment of schizophrenia.

The generics of Aristada Initio Kit are possible to be released after 06 April, 2039.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10112903 ALKERMES INC Heterocyclic compounds for the treatment of neurological and psychological disorders
Jun, 2030

(7 years from now)

US8431576 ALKERMES INC Heterocyclic compounds for the treatment of neurological and psychological disorders
Oct, 2030

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8796276 ALKERMES INC Heterocyclic compounds for the treatment of neurological and psychological disorders
Jun, 2030

(7 years from now)

US11154552 ALKERMES INC Aripiprazole prodrug composition
Aug, 2035

(12 years from now)

US10849894 ALKERMES INC Aripiprazole prodrug composition
Aug, 2035

(12 years from now)

US10688091 ALKERMES INC Aripiprazole prodrug composition
Aug, 2035

(12 years from now)

US10016415 ALKERMES INC Aripiprazole prodrug compositions
Sep, 2035

(12 years from now)

US11273158 ALKERMES INC Aripiprazole dosing strategy
Apr, 2039

(16 years from now)

Drugs and Companies using ARIPIPRAZOLE LAUROXIL ingredient

Market Authorisation Date: 29 June, 2018

Treatment: Treatment of schizophrenia

Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic